ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 189

Influenza Immunization: A Quality Assurance Survey in a Pediatric Rheumatology Clinic

Charlene Hopper1 and Gaelle Chedeville 2, 1MCH-MUHC, Montreal, Quebec, Canada, 2The Montreal Children's Hospital, Montreal, Quebec, Canada

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: Influenza, vaccine

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Saturday, May 2, 2020

Title: Poster Session 3

Session Type: ACR Abstract Session

Session Time: 4:15PM-5:15PM

Background/Purpose: EULAR guidelines recommend that annual influenza immunization be considered for all children with pediatric rheumatic diseases based on the possible increased risk of flu infection and the safety and immunogenicity of the vaccine. In accordance with these guidelines our division advices influenza immmunization for children and their families that are more at risk because of their disease or treatment. Despite our yearly recommendation with a flu vaccine letter and discussion with parents, there has been no systematic evaluation of who receives this vaccine. The purpose of this survey was to better understand families’ decision making around influenza immunization and how to better promote it for at risk children and their families.

Methods: From March to May 2019 families were invited, at the time of registration for their rheumatology visit, to fill a short survey related to influenza immunization. Eligibility was screened by the nurse and communicated to the clinic receptionist. Surveys were available in French and English and took 2-5 minutes to complete. Questions offered preselected responses with tick boxes and space to write additional comments. The questions explored who received the vaccine, why/why not, whether they received a reminder, barriers to vaccination and beliefs about risk. Families returned the completed survey to the receptionist or the nurse.

Results: The survey had an 88% response rate. The majority of the children were followed for Juvenile Idiopathic Arthritis (67%). For the immunization period 2018-2019, 111 (49%) of the 228 respondents received the flu vaccine. The vaccine was done for both the child and family members 86% of the time. Most received the vaccine at their local community clinic. Out of 100 respondents reporting receiving our reminder letter, 72 had the flu vaccine. Children vaccinated were on no treament in 41%, on non-steroidal anti-inflammatory drugs in 20%, on methotrexate (MTX) alone in 52%, on MTX and a biologic in 67%, and on a biologic alone in 84%.

Some families, whose children were on immunosuppressive medications identified that they felt their child was more likely to get the flu and/or to become more ill than other children if they had the flu. Of those, 79% chose to have their child vaccinated.

Families who vaccinated their child did so for a variety of reasons, the most important being to protect their child. Families who decided not to vaccinate most commonly felt that the vaccine was not always effective. Having easier access to the flu vaccine, as well as reassurance about safety and efficacy were identified as factors that would make it easier to receive the flu vaccine.

Conclusion: While a fairly high proportion of families indicate choosing the flu vaccine for their child and family, there is still room for improvement. For the season 2019-2020 we included a letter of information, attached to our regular flu vacine reminder letter, to address concerns identified as important to families. A poster with the findings of the survey  was placed in the clinic to stimulate conversation with families. Eliciting parents’ perception of their child’s risk of influenza illness should be part of our conversation, as this seems to be an important influence on choosing to vaccinate.


Disclosure: C. Hopper, None; G. Chedeville, None.

To cite this abstract in AMA style:

Hopper C, Chedeville G. Influenza Immunization: A Quality Assurance Survey in a Pediatric Rheumatology Clinic [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/influenza-immunization-a-quality-assurance-survey-in-a-pediatric-rheumatology-clinic/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/influenza-immunization-a-quality-assurance-survey-in-a-pediatric-rheumatology-clinic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology